Did the COVID-19 pandemic increase drunkness among people with a history of alcohol use disorder?

Al­ny­lam’s zilebe­sir­an met the pri­ma­ry end­point and cer­tain sec­ondary end­points in a Phase II dose-rang­ing tri­al in a read­out that ar­rived less than six weeks

Share this article The company’s candidates ALTO-100, ALTO-202 and ALTO-300 are all developed for depression, with ALTO-100 also being developed for post-traumatic stress disorder. Image